Journal of Neuro-Ophthalmology:
Neuro-Ophthalmological Features of Primary Diffuse Leptomeningeal Gliomatosis
Noval, Susana MD, PhD; Ortiz-Pérez, Santiago MD; Sánchez-Dalmau, Bernardo F. MD; Ruiz-Ares, Gerardo MD; Arpa, Javier MD, PhD; Adán, Alfredo MD, PhD
Departments of Ophthalmology (SN) and Neurology (GR-A, JA), Hospital University La Paz, Madrid, Spain; Vissum Mirasierra (SN), Madrid, Spain; Department of Ophthalmology (SO-P, BFS-D, AA), Hospital University Clinic I Provincial, Barcelona, Spain; Institut Clínic d'Oftalmologia (BFS-D), Barcelona, Spain; and Instituto de Microcirugía Ocular (AA). Barcelona, Spain.
The authors report no conflicts of interest.
Address correspondence to Susana Noval MD, PhD, Melchor Fernández Almagro St. 18 6°A, Madrid 28029, Spain; E-mail: email@example.com
Abstract: We performed an in-depth study of the neuro-ophthalmologic signs and symptoms of a rare but fatal disease known as primary diffuse leptomeningeal gliomatosis (PDLG). Two new cases of PDLG are described, and 22 published cases reviewed. Papilledema and sixth nerve palsy are the most common neuro-ophthalmic findings. Other abnormalities include third and fourth nerve palsies, nystagmus, and vision loss. Involvement of the visual system may be part of the initial presentation of PDLG.
Primary diffuse leptomeningeal gliomatosis (PDLG) is a rare and fatal disease characterized by diffuse infiltration of the meninges by neoplastic glial cells without evidence of tumor within the parenchyma of the brain or spinal cord. These neoplastic cells are thought to arise from heterotopic glial nests in the leptomeninges (1,2). Cooper and Kernohan (3) proposed the following diagnostic criteria: no apparent attachment of extramedullary meningeal tumor to the neural parenchyma, no evidence of primary neoplasia within the neuraxis, and the existence of distinct leptomeningeal encapsulation around the tumor. The mean age of clinical onset is 34 years, but it may appear at any age, ranging from 1 to 80 years (1,2,4). PDLG shows male predominance (5). The most striking features include rapid onset, short prodromal phase, and an aggressive course. Clinical presentation includes a variety of neurological symptoms, including headache, cranial nerve involvement, vomiting, meningismus, and decreased mental status (4). Raised intracranial pressure is the most constant sign as a result of communicating hydrocephalus, with papilledema and sixth nerve palsy as the most frequent neuro-ophthalmic signs reported (1,6). Visual symptoms are often vague at initial clinical presentation (7), and blindness usually develops late in the course of the disease (1,8,9).
Diagnosis of PDLG is often challenging because the clinical picture is similar to chronic infectious meningitis or polyradiculopathy, and cerebrospinal fluid (CSF) analysis is frequently nonspecific (5,10). Tuberculous meningitis is often suspected as the initial diagnosis, and patients may be started on antituberculosis therapy (1).
We describe 2 patients with PDLG who presented with prominent visual symptoms. Their clinical course is added to the clinical profile of other cases of PDLG.
A 19-year-old woman was seen in consultation for headaches and behavioral changes. Six days later, she complained of a sudden reduction of vision in the right eye. Bilateral sixth nerve palsies and neck stiffness developed rapidly. On examination, visual acuity was light perception, right eye, and 20/20, left eye, and bilateral papilledema was noted. Brain MRI and MRA were unremarkable. Lumbar puncture demonstrated an elevated opening pressure of 50 cm H2O with low glucose of 29 mg/dL (normal: 55–75 mg/dL), increased protein of 49 mg/dL (normal: 15–45 mg/dL), and 10 white blood cells per cubic millimeter.
Treatment for presumed tuberculous meningitis was started with isoniazid, rifampicin, ethambutol, pyrazinamide, and prednisone. However, visual acuity fell to light perception in both the eyes, with pupils reacting poorly to light. Within one month, diffuse optic atrophy was present bilaterally.
Blood tests, immunologic studies, and tumoral markers were normal. Repeat lumbar puncture revealed CSF adenosine deaminase activity of 21.9 U/L (>20 U/L supportive of the diagnosis of tuberculous meningitis). CSF cultures and serologies were negative, and cytology did not show the presence of malignant cells. Brain and meningeal biopsies were nondiagnostic. Six weeks after the onset of symptoms, MRI revealed widespread meningeal thickening of the brain and the spinal cord and enhancing nodular lesions (Fig. 1).
The patient continued to deteriorate clinically developing respiratory insufficiency and tetraparesis. She died 22 weeks after the presentation. Postmortem examination revealed diffuse, whitish, granular thickening of the meninges. The subarachnoid space was infiltrated with glial cells, which had numerous Rosenthal fibers and expressed glial fibrillary acidic protein and the p53 gene (Fig. 2A). The glial cells surrounded and compressed the vasculature, some cranial nerves, and the pineal gland. The lower brainstem showed extensive hemorrhagic necrosis. No evidence of a primary tumor was found in the brain or spinal cord parenchyma.
A 17-year-old woman presented with generalized weakness, vomiting, and epigastric pain, and 4 days later, she developed diplopia. Examination documented vision of 20/20 in both eyes, with bilateral sixth nerve palsies and a partial right third nerve palsy. Three days later, she complained of visual impairment in the right eye and was found to have acuity of light perception, right eye and 20/20, left eye. A right relative afferent pupillary defect was detected, and the fundi were normal. Optic disc pallor developed in the right eye over the course of several weeks.
Brain MRI demonstrated diffuse leptomeningeal enhancement without evidence of intraparenchymal lesions (Fig. 3A). Analysis of CSF did not show malignant cells but increased protein of 77 mg/dL (normal: 15–48 mg/dL), pleocytosis (10 white blood cells/mm3), and low glucose of 27 mg/dL (normal: 55–75 mg/dL) were detected. A diagnosis of probable tuberculous meningitis was made, and an empiric treatment with antituberculous medications and steroids was initiated.
The patient developed cognitive dysfunction, meningeal signs, and hydrocephalus that required placement of a ventriculoperitoneal shunt. Follow-up brain MRI showed additional lesions in the subarachnoid space including the skull base and the spinal cord (Fig. 3B). A brain biopsy was performed, which disclosed anaplastic glial cells within the leptomeninges consistent with PDLG (Fig. 2B, C). Treatment included radiotherapy (brain, spinal cord) and chemotherapy with temozolomide. No significant improvement was observed. The patient slowly deteriorated and died due to respiratory failure 15 months after initial presentation.
PDLG is a rare condition that produces a clinical picture similar to chronic infectious meningitis (9). Due to the variability of clinical presentation, clinical diagnosis is often challenging, and meningeal biopsy is required (1). Differential diagnosis includes infectious meningoencephalitis, meningeal carcinomatosis, secondary meningeal gliomatosis, and autoimmune and inflammatory diseases affecting the meninges (11,12).
Early in the course of the disease, MRI of the central nervous system may be normal. With progression of the disease, ventriculomegaly and diffuse or focal contrast-enhancing leptomeningeal thickening with no discernible intraaxial component are the most frequent neuroimaging findings. These leptomeningeal abnormalities may be restricted to the spinal cord or may be associated with contrast enhancement of the basal cisterns, cerebellum, brainstem, and cerebral hemispheres. Ischemic changes have also been reported and may be secondary to vascular compression by the neoplastic cells (1,4,6). As in our 2 patients, analysis of the CSF is often nondiagnostic demonstrating changes consistent with meningitis (1,9,13,14). Malignant cells were not detected in any of the CSF cytology studies performed in our patients, similar to previous reports of PDLG (1,11,15).
Meningeal biopsy is necessary to confirm the diagnosis of PDLG. The leptomeninges are usually diffusely affected at the skull base and around the brainstem, while skip areas are found over the convexities, explaining the failure of some diagnostic biopsies, as in our first patient (4,6,10,15–17). It has been recommended that the biopsy be performed with MRI guidance to improve the diagnostic accuracy (16). At times, the histopatholgic features of PDLG may resemble other neoplasms of the central nervous system, including oligodendroglioma, astrocytoma, ependymoblastoma, primitive neuroectodermal tumor and glioblastoma multiforme (15,18–20).
Papilledema has been noted in most cases, but it may be detected without ocular symptoms (9,16,21). Table 1 summarizes PDLG cases in which visual symptoms or signs have been reported. While visual loss usually occurs in the late stages of PDLG, it may occur early in the course of the disease (10,23), as in our 2 patients. Double vision is the most common visual complaint, primarily due to sixth nerve palsy. Third nerve palsy has been described in 4 patients (4,22,23), including our case 2, and only 1 reported patient presented vertical diplopia due to fourth nerve palsy (14). Cranial nerves have been involved in more than half of the published cases of PDLG (24). Intracranial pressure may be the cause of most sixth nerve palsies, but diplopia is not always accompanied by papilledema (2), and direct infiltration of the ocular motor nerves has been found in many cases (1,18,22–24). Nystagmus has also been documented in the course of the disease and is typically gaze evoked (4).
TABLE 1-a Literature...Image Tools
Our patients showed early, severe, and irreversible visual loss. This developed in spite of steroid therapy and, in the first case, persisted after the immediate placement of external CSF drainage. Our second patient developed light perception in 1 eye in the absence of optic disc edema. Clearly, visual loss in PDLG may occur by mechanisms other than raised intracranial pressure. Direct tumor infiltration of the anterior visual pathways is one potential cause (1,17). Another is a focal vasculitic process due to the extension of tumor cells along the Virchow-Robin spaces that surround the cerebral vasculature (4,24,25). This may lead to an occlusive vasculopathy (2,26), causing not only visual loss but brainstem ischemia as well.
TABLE 1-b Literature...Image Tools
Currently, there is no curative treatment for PDLG. Brain and spinal radiotherapy and a variety of chemotherapeutic agents have been used. The combination of temozolomide with radiotherapy has been suggested to improve the prognosis of PDLG (7,12). Jicha et al (5) treated 4 patients in this manner, achieving clinical stability for at least 8 months in 3 patients, and 1 patient remains alive at 41 months. This protocol was used in our second case, and only a partial response was observed with survival of 15 months. In general, even the most aggressive treatment regimens have achieved limited survival periods of less than 2 years (16).
1. Baborie A, Dunn EM, Bridges LR, Bamford JM. Primary diffuse leptomeningeal gliomatosis predominantly affecting the spinal cord: case report and review of the literature. J Neurol Neurosurg Psychiatry. 2001;70:256–258
2. Debono B, Derrey S, Rabehenoina C, Proust F, Freger P, Laquerriere A. Primary diffuse multinodular leptomeningeal gliomatosis: case report and review of the literature. Surg Neurol. 2006;65:273–282
3. Cooper IS, Kernohan JW. Heterotopic glial nests in the subarachnoid space; histopathologic characteristics, mode of origin and relation to meningeal gliomas. J Neuropathol Exp Neurol. 1951;10:16–29
4. Yomo S, Tada T, Hirayama S, Tachibana N, Otani M, Tanaka Y, Hongo K. A case report and review of the literature. J Neurooncol. 2007;81:209–216
5. Jicha GA, Glantz J, Clarke MJ, Lehwald LM, Russo DP, Giannini C, Wald JT, Uhm J, Kumar N, Aksamit AJ, Wetmore CJ. Primary diffuse leptomeningeal gliomatosis. Eur Neurol. 2009;62:16–22
6. Corsten LA, Raja AI, Wagner FC Jr. Primary diffuse leptomeningeal gliomatosis. Br J Neurosurg. 2001;15:62–66
7. Franceschi E, Cavallo G, Scopece L, Esposti RD, Paioli G, Paioli A, Palmerini E, Foschini MP, Marliani AF, Crino L. Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis. J Neurooncol. 2005;73:261–264
8. Paulino AC, Thomas C, Slomiany DJ, Suarez CR. Diffuse malignant leptomeningeal gliomatosis in a child: a case report and review of the literature. Am J Clin Oncol. 1999;22:243–246
9. Rees JH, Balakas N, Agathonikou A, Hain SF, Giovanonni G, Panayiotopoulos CP, Luxsuwong M, Revesz T. Primary diffuse leptomeningeal gliomatosis simulating tuberculous meningitis. J Neurol Neurosurg Psychiatry. 2001;70:120–122
10. Ko MW, Turkeltaub PE, Lee EB, Gonatas NK, Volpe NJ, Moster ML, Galetta SL. Primary diffuse leptomeningeal gliomatosis mimicking a chronic inflammatory meningitis. J Neurol Sci. 2009;278:127–131
11. Riva M, Bacigaluppi S, Galli C, Citterio A, Collice M. Primary leptomeningeal gliomatosis: case report and review of the literature. Neurol Sci. 2005;26:129–134
12. Watanabe Y, Hotta T, Yoshioka H, Itou Y, Taniyama K, Sugiyama K. Primary diffuse leptomeningeal gliosarcomatosis. J Neurooncol. 2008;86:207–210
13. Leproux F, Melanson D, Mercier C, Michaud J, Ethier R. Leptomeningeal gliomatosis: MR findings. J Comput Assist Tomogr. 1993;17:317–320
14. Trivedi RA, Nichols P, Coley S, Cadoux-Hudson TA, Donaghy M. Leptomeningeal glioblastoma presenting with multiple cranial neuropathies and confusion. Clin Neurol Neurosurg. 2000;102:223–226
15. Dietrich PY, Aapro MS, Rieder A, Pizzolato GP. Primary diffuse leptomeningeal gliomatosis (PDLG): a neoplastic cause of chronic meningitis. J Neurooncol. 1993;15:275–283
16. Beauchesne P, Pialat J, Duthel R, Barral FG, Clavreul G, Schmitt T, Laurent B. Aggressive treatment with complete remission in primary diffuse leptomeningeal gliomatosis–a case report. J Neurooncol. 1998;37:161–167
17. Bhrany D, Murphy MG, Horenstein S, Silbert SW. Diffuse periventricular and meningeal glioma. Acta Neuropathol. 1974;30:243–249
18. Giordana MT, Bradac GB, Pagni CA, Marino S, Attanasio A. Primary diffuse leptomeningeal gliomatosis with anaplastic features. Acta Neurochir (Wien). 1995;132:154–159
19. Ng HK, Poon WS. Diffuse leptomeningeal gliomatosis with oligodendroglioma. Pathology. 1999;31:59–63
20. Bailey P, Robitaille Y. Primary diffuse leptomeningeal gliomatosis. Can J Neurol Sci. 1985;12:278–281
21. Bilic M, Welsh CT, Rumboldt Z, Hoda RS. Disseminated primary diffuse leptomeningeal gliomatosis: a case report with liquid based and conventional smear cytology. Cytojournal. 2005;20:16
22. Sumi SM, Leffman H. Primary intracranial leptomeningeal glioma with persistent hypoglycorrhachia. J Neurol Neurosurg Psychiatry. 1968;31:190–194
23. Olivera-Leal IR, Gomez-Viera N, Gonzalez-Espinosa L, Borrajero-Martinez I, varez-Santana R, Cubero-Rego D. [Primary diffuse leptomeningeal gliomatosis. Presentation of one case]. Rev Neurol. 1997;25:1419–1421
24. Davila G, Duyckaerts C, Lazareth JP, Poisson M, Delattre JY. Diffuse primary leptomeningeal gliomatosis. J Neurooncol. 1993;15:45–49
25. Tsui EY, Loo KT, Mok CK, Yuen MK, Cheung YK. Primary multifocal leptomeningeal gliomatosis. Eur J Radiol. 2001;37:5–7
26. Moonis M, Smith TW. Meningeal gliomatosis presenting as multiple cerebral infarcts: a case report. Neurology. 1996;46:1760–1762
27. Kitahara M, Katakura R, Wada T, Namiki T, Suzuki J. Diffuse form of primary leptomeningeal gliomatosis. Case report. J Neurosurg. 1985;63:283–287
28. Rogers LR, Estes ML, Rosenbloom SA, Harrold L. Primary leptomeningeal oligodendroglioma: case report. Neurosurgery. 1995;36:166–168
29. Kobayashi M, Hara K, Nakatsukasa M, Murase I, Toya S. Primary spinal leptomeningeal gliomatosis presenting visual disturbance as the initial symptom: case report. Acta Neurochir (Wien). 1996;138:480–481
30. Verslegers I, Demaerel P, Van CF, Sciot R. Primary multifocal leptomeningeal gliomatosis. Pediatr Radiol. 1998;28:580–582
31. Bohner G, Masuhr F, Distl R, Katchanov J, Klingebiel R, Zschenderlein R, von DA, van Landeghem FK. Pilocytic astrocytoma presenting as primary diffuse leptomeningeal gliomatosis: report of a unique case and review of the literature. Acta Neuropathol. 2005;110:306–311
This article has been cited 1 time(s).
Journal of the Neurological SciencesMalignant meningitis presenting as pseudotumor cerebriJournal of the Neurological Sciences
© 2011 Lippincott Williams & Wilkins, Inc.